Bicycle Therapeutics/BCYC

$22.30

-0.88%
-
1D1W1MYTD1YMAX

About Bicycle Therapeutics

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Ticker

BCYC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kevin Lee

Employees

284

Headquarters

Cambridge, United Kingdom

BCYC Metrics

BasicAdvanced
$979.06M
Market cap
-
P/E ratio
-$5.13
EPS
0.90
Beta
-
Dividend rate
$979.06M
0.89829
$28.91
$12.54
381.09K
8.08
8.276
8.276
-35.92%
-56.31%
-40.92%
36.294
2.63
2.639
86.52%
-34.98%
37.44%

What the Analysts think about BCYC

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 10 analysts.
93.72% upside
High $60.00
Low $30.00
$22.30
Current price
$43.20
Average price target

BCYC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-924.52% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$5.3M
0%
Net income
$-49M
-1.61%
Profit margin
-924.52%
-1.61%

BCYC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.95%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.30
-$1.41
-$1.26
-$1.16
-
Expected
-$1.07
-$1.29
-$1.17
-$1.23
-$1.24
Surprise
21.15%
9.02%
7.56%
-5.95%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Bicycle Therapeutics stock?

Bicycle Therapeutics (BCYC) has a market cap of $979.06M as of April 12, 2024.

What is the P/E ratio for Bicycle Therapeutics stock?

The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of April 12, 2024.

Does Bicycle Therapeutics stock pay dividends?

No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of April 12, 2024.

When is the next Bicycle Therapeutics dividend payment date?

Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.

What is the beta indicator for Bicycle Therapeutics?

Bicycle Therapeutics (BCYC) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Bicycle Therapeutics stock price target?

The target price for Bicycle Therapeutics (BCYC) stock is $43.2, which is 93.72% above the current price of $22.3. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Bicycle Therapeutics stock

Buy or sell Bicycle Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing